52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Abbott Receives U.S. FDA Clearance For New Cardiac Mapping System To Improve How Doctors Treat Abnormal Heart Rhythms
Abbott Names Robert B. Ford Chairman Of The Board Miles D. White To Retire As Executive Chairman
Abbott Increases Quarterly Dividend For 50Th Consecutive Year
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its products include a line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The Company’s products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. It offers cardiovascular and metabolic products, including Lipanthyl, TriCor, Teveten, Teveten Plus, Physiotens, and Synthroid.
Medical Equipment & Supplies
100 Abbott Park Rd
ABBOTT PARK, IL
Robert B. Ford
Chairman of the Board and Chief Executive Officer
Robert E. Funck
Chief Financial Officer, Executive Vice President - Finance
Hubert L. Allen
Executive Vice President, General Counsel, Secretary
Mary K. Moreland
Executive Vice President of Human Resources
John M. Capek
Executive Vice President - Ventures
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
* ABBOTT LABORATORIES EXEC SAYS SAW BIG SURGE IN THE UNITED STATES AND INTERNATIONALLY IN COVID-19 TEST DEMAND FOR DIAGNOSING AND SCREENING AROUND THANKSGIVING AND CHRISTMAS- JPM CONF
Abbott Laboratories Chief Executive Officer Robert Ford said on Tuesday demand for COVID-19 testing has surged globally and that sales of its tests should stay strong in the near term.
More than 30 lawsuits claiming that cows' milk baby formula products cause a dangerous medical condition in premature infants have been filed against the makers of Enfamil and Similac in Illinois state courts since February, and plaintiffs’ firm Keller Lenkner is seeking...
An Abbott Laboratories subsidiary focused on diabetes care sued rival DexCom in Delaware federal court for allegedly violating a 2014 settlement agreement and asked the court to declare that Abbott doesn't infringe its patents.
Abbott Laboratories said demand for its COVID-19 tests, especially rapid testing, rebounded as the U.S. wrestled with surging coronavirus cases during the quarter, prompting the company to raise its earnings forecast for the year.
* ABBOTT CEO SAYS COMPANY SOLD MORE THAN 225 MILLION COVID TESTS GLOBALLY IN THIRD QUARTER: CONF CALL
Abbott Laboratories reported a 70.5% rise in quarterly profit on Wednesday, helped by strength in its medical device and diagnostics businesses and a rebound in COVID-19 test sales due to the spread of the Delta variant of the coronavirus.
A unit of Abbott Laboratories is recalling two COVID-19 laboratory test kits as they can potentially issue false positive results, the U.S. Food and Drug Administration (FDA) said on Thursday.
A unit of Abbott Laboratories is recalling two COVID-19 test kits as they can potentially issue false positive results, the U.S. Food and Drug Administration (FDA) said on Thursday.
The U.S. government has agreed to purchase rapid COVID-19 tests from Abbott Laboratories and Celltrion Inc to ship to nursing homes and other high risk populations as part of President Joe Biden's vaccinate or test plans, a senior administration official said on Tuesday.
Abbott Laboratories will pay $160 million to resolve claims that two of its units submitted false claims to Medicare by providing kickbacks to diabetes patients, including "free" or "no cost" glucose monitors, the U.S. Department of Justice said.
Two units of Abbott Laboratories will pay $160 million to resolve claims they violated the federal False Claims Act by submitting false claims to Medicare, the U.S. Department of Justice said on Monday.
Abbott Laboratories beat quarterly profit estimates on Thursday, driven by a rebound in its non-COVID-19 testing business and sales of its medical devices as vaccinations encouraged Americans to resume non-urgent procedures.
Abbott Laboratories quarterly profit more than doubled on Thursday, due to strength in its diagnostics business and a rebound in medical devices sales.
St. Jude Medical, which was acquired by Abbott Laboratories in 2017, has agreed to pay $27 million to settle allegations it knowingly sold defective heart devices, the U.S. Justice Department said on Thursday.
Abbott Laboratories on Tuesday cut its full-year 2021 profit forecast as it expects a sharp decline in revenue from its COVID-19 tests as more Americans get vaccinated, sending the medical device maker's shares down more than 6%.
Abbott Laboratories on Tuesday forecast 2021 profit below analysts' estimates, due to lower projected COVID-19 diagnostic testing demand.
Quest Diagnostics Inc on Thursday reported a first-quarter profit that exceeded Wall Street expectations as a recovery in its non-COVID-19 businesses offset a slowdown in coronavirus testing.
Abbott Laboratories fell short of first-quarter revenue estimates on Tuesday due to easing demand for some of its COVID-19 tests, stoking fears of slowing growth for the business as vaccinations gain steam across the globe.
Abbott Laboratories reported a more than threefold jump in quarterly profit on Tuesday, buoyed by robust demand for its COVID-19 test kits and growth in its diabetes and nutrition businesses.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.